EXEL

Exelixis, Inc.

A biopharmaceutical company that makes cancer medicines, most notably cabozantinib, sold in the U.S. as CABOMETYX for kidney and liver cancers and as COMETRIQ for a rare thyroid cancer. Founded in 1994 by scientists from Yale and UC Berkeley who began by studying fruit flies and zebrafish to find drug targets, the company is now a fully integrated oncology drugmaker. Its name comes from the Greek word for "evolution," a nod to how the firm itself evolved from a genomics startup into a commercial drug company.

CUSIP: 30161Q104HealthcareUS2 holders

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 5 years

Insider

Morrissey MichaelPresident and CEO, Director · 82 transactions

8.36M+158.1%

Granted 5.20M

Caligan Partners LP +1 co-filerDirector, See Remarks, Director · 7 transactions

1.57M—

Granted 18.2K · Bought 762.9K · Sold 120.4K

Papadopoulos SteliosDirector · 13 transactions

1.20M-8.2%

Granted 125.5K · Sold 232.5K

Senner Christopher J.EVP and CFO · 56 transactions

955.0K+165.8%

Granted 1.73M · Sold 474.1K

Haley Patrick J.EVP, Commercial · 82 transactions

783.2K+66.6%

Granted 1.36M · Sold 850.2K

Hessekiel JeffreyEVP & General Counsel · 61 transactions

694.4K+14.6%

as of May 2025

Granted 1.06M · Sold 604.5K

Aftab DanaEVP, Research and Development · 48 transactions

600.6K—

Granted 1.13M · Sold 499.3K

Peterson Amy C.EVP Prod Dev & Med Aff & CMO · 8 transactions

538.2K—

as of May 2025

Granted 573.7K · Sold 72.8K

Willsey LanceDirector · 2 transactions

464.4K+9.4%

as of May 2022

Granted 40.0K · Sold 40.0K

Lamb PeterEVP, Scientific Strategy & CSO · 24 transactions

428.1K-7.3%

as of Dec 2022

Granted 346.1K · Sold 210.0K

Goodman Vicki LEVP, Prod Dev & Med Aff &CMO · 4 transactions

307.7K—

as of Apr 2023

Granted 332.6K

Wyszomierski Jack LDirector · 18 transactions

284.4K+18.5%

Granted 205.5K · Sold 161.0K

Hefti BrendaSVP and General Counsel · 6 transactions

208.3K—

Granted 53.3K · Sold 25.3K

Poste GeorgeDirector · 16 transactions

127.2K-26.7%

Granted 165.5K · Sold 211.9K

Freire Maria CDirector · 11 transactions

109.2K+172.1%

Granted 142.1K · Sold 73.0K

Marchesi Vincent TDirector · 1 transaction

94.0K+26.3%

as of May 2022

Granted 19.6K

Feldbaum Carl BDirector · 7 transactions

58.7K+105.8%

as of Feb 2023

Granted 90.2K · Sold 80.0K

Garber Alan MDirector · 6 transactions

54.9K+4.2%

as of Mar 2024

Granted 103.5K · Sold 80.5K

Wright JacquelineDirector · 3 transactions

51.8K—

as of Jun 2023

Granted 51.8K

Heyman Tomas J.Director · 5 transactions

50.6K—

Granted 55.2K · Sold 4.5K

Oliver BobDirector · 10 transactions

29.5K—

Granted 79.4K · Sold 48.9K

Smith JulieDirector · 16 transactions

29.0K-11.5%

Granted 208.5K · Sold 207.6K

Beckerle Mary CDirector · 12 transactions

25.9K—

Granted 70.4K · Sold 44.5K

Eckhardt Sue GailDirector · 11 transactions

16.1K—

Granted 60.2K · Sold 44.1K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Morrissey MichaelPresident and CEO, Director · 82 transactions	+158.1%	8.36M	5.20M	—	—
Caligan Partners LP +1 co-filerDirector, See Remarks, Director · 7 transactions	—	1.57M	18.2K	762.9K	120.4K
Papadopoulos SteliosDirector · 13 transactions	-8.2%	1.20M	125.5K	—	232.5K
Senner Christopher J.EVP and CFO · 56 transactions	+165.8%	955.0K	1.73M	—	474.1K
Haley Patrick J.EVP, Commercial · 82 transactions	+66.6%	783.2K	1.36M	—	850.2K
Hessekiel JeffreyEVP & General Counsel · 61 transactions	+14.6%	694.4Kas of May 2025	1.06M	—	604.5K
Aftab DanaEVP, Research and Development · 48 transactions	—	600.6K	1.13M	—	499.3K
Peterson Amy C.EVP Prod Dev & Med Aff & CMO · 8 transactions	—	538.2Kas of May 2025	573.7K	—	72.8K
Willsey LanceDirector · 2 transactions	+9.4%	464.4Kas of May 2022	40.0K	—	40.0K
Lamb PeterEVP, Scientific Strategy & CSO · 24 transactions	-7.3%	428.1Kas of Dec 2022	346.1K	—	210.0K
Goodman Vicki LEVP, Prod Dev & Med Aff &CMO · 4 transactions	—	307.7Kas of Apr 2023	332.6K	—	—
Wyszomierski Jack LDirector · 18 transactions	+18.5%	284.4K	205.5K	—	161.0K
Hefti BrendaSVP and General Counsel · 6 transactions	—	208.3K	53.3K	—	25.3K
Poste GeorgeDirector · 16 transactions	-26.7%	127.2K	165.5K	—	211.9K
Freire Maria CDirector · 11 transactions	+172.1%	109.2K	142.1K	—	73.0K
Marchesi Vincent TDirector · 1 transaction	+26.3%	94.0Kas of May 2022	19.6K	—	—
Feldbaum Carl BDirector · 7 transactions	+105.8%	58.7Kas of Feb 2023	90.2K	—	80.0K
Garber Alan MDirector · 6 transactions	+4.2%	54.9Kas of Mar 2024	103.5K	—	80.5K
Wright JacquelineDirector · 3 transactions	—	51.8Kas of Jun 2023	51.8K	—	—
Heyman Tomas J.Director · 5 transactions	—	50.6K	55.2K	—	4.5K
Oliver BobDirector · 10 transactions	—	29.5K	79.4K	—	48.9K
Smith JulieDirector · 16 transactions	-11.5%	29.0K	208.5K	—	207.6K
Beckerle Mary CDirector · 12 transactions	—	25.9K	70.4K	—	44.5K
Eckhardt Sue GailDirector · 11 transactions	—	16.1K	60.2K	—	44.1K

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.